TILS.L Regulatory News (TILS)

1 Oct 2007 07:01

ReGen Therapeutics PLC01 October 2007 ReGen's Cognitive Nutraceutical Colostrinin TM Launched in USA ColostrininTM to be active ingredient in Metagenics' CogniSureTM, a productbeing marketed as support for the maintenance of mental capacity ReGen Therapeutics Plc (London) announced today that its licensee Metagenics,Inc. has launched its cognitive nutraceutical, ColostrininTM, onto the USmarket. Metagenics Inc. is a leading supplier of natural medicines to healthcareprofessionals. ColostrininTM is the active ingredient in Metagenics' healthy cognition supportformula, CogniSureTM. Initially CogniSureTM is being made available to consumersvia Metagenics' network of approximately 30,000 healthcare professionals acrossthe USA. These include physicians, chiropractors, acupuncturists, nutritionists,and other healthcare professionals with a specific interest in nutritionalsupplementation. The product is being made available as chocolate flavourchewable tablets in blister packs containing 30 tablets. Further details ofavailability are provided on Metagenics' website (www.metagenics.com).Commercial partners for subsequent retail channel distribution are currentlybeing sought by ReGen and Metagenics. The financial terms of this deal remain commercially confidential, although itcan be confirmed that all agreements with Metagenics involve the sale and supplyof the ColostrininTM active ingredient to Metagenics for them to formulate,package and market. ReGen then receives a royalty out of the sale proceeds whenthe formulated product is sold. Percy Lomax, Executive Chairman of ReGen said, "After the successful launch ofColostrininTM in Australasia in July, the launch of ColostrininTM "asCogniSureTM" in the USA is a major milestone for ReGen. The USA is by far thelargest natural medicines market in the world and we are therefore excited bythe possibilities for sales." Dr. Jeffrey Bland, CSO and President of MetaProteomics(R) (a subsidiary ofMetagenics) , added, "We are very pleased to be introducing ColostrininTM to theUSA. Based on feedback from customers in Australia and New Zealand and interestamongst practitioners here, we are optimistic that it will be well received inthe USA and believe it will be an important breakthrough in helping to maintainthe cognitive health of the ageing population here." Further information: Percy Lomax Chairman and Chief Executive ReGen Therapeutics Plc Tel: 020 7153 4920 Direct: 020 8504 2156 Mobile: 07932 751541 Andrew Marshall Greycoat Communications Tel: 020 7960 6007 Mobile: 07785 297111 Roland Cornish Beaumont Cornish Limited Tel: 020 7628 3396 Notes to Editors About ReGen Therapeutics PlcReGen Therapeutics is a UK listed Biotech company which is developing threebusiness lines-human and veterinary nutraceuticals, prescription pharmaceuticalsfor the treatment of neurodegenerative diseases and a clinical researchorganisation which oversees Phase I and Phase II both for ReGen and externalcustomers. ReGen's business strategy is to develop its nutraceutical andpharmaceutical products to a state where they can be licensed out and marketedby a third party. Its only direct sales are currently through its clinicalresearch organisation: www.regentherapeutics.com ReGen's shares are traded on the AIM Market of the London Stock Exchange plc(RGT) and are quoted on the Pink Sheets of the United States over-the-countermarket in the form of American Depositary Receipts (REGUY:PK). About Metagenics, Inc.Metagenics is a life sciences company and leading developer and manufacturer ofscience-based medical foods and nutraceuticals sold to healthcare practitionersworldwide. It is headquartered in San Clemente, CA, with manufacturing andresearch facilities located in Gig Harbor, WA, including the MetaProteomics(R)Nutrigenomics Research Center and the Functional Medicine Research CenterSM forhuman clinical research. Metagenics holds multiple proprietary formula patentsand produces more than 400 research-based products to optimize health. Thecompany demonstrates its commitment to purity and quality through itscertifications for Good Manufacturing Practices (GMP) from the NPA, NSFInternational, and TGA. For more information, please visit www.metagenics.com. This information is provided by RNS The company news service from the London Stock Exchange